Filter Results:
(200)
Show Results For
- All HBS Web (200)
- Faculty Publications (76)
Show Results For
- All HBS Web (200)
- Faculty Publications (76)
E. Gifford Upjohn
Upjohn played an instrumental role in supporting legislation requiring pharmaceutical companies to prove a drug’s effectiveness in clinical trials prior to its general release. A physician by training, Upjohn established the Medical... View Details
Keywords: Healthcare
Melvin R. Goodes
Goodes grew Warner-Lambert’s market value from $9 billion in 1991 to almost $60 billion in 1999. He helped the pharmaceutical company become a major player in the prescription drug industry and is responsible for striking a deal with... View Details
Keywords: Personal Care & Home Products
John G. Searle
The pharmaceutical company that John Searle inherited from his father was moderately successful, with about $1 million in sales in 1936, but under Searle’s guidance the company grew rapidly. G. D. Searle’s... View Details
Keywords: Healthcare
- 06 May 2008
- First Look
First Look: May 6, 2008
company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global... View Details
Keywords: Martha Lagace
- September 1983 (Revised November 1984)
- Case
Syntex Laboratories (B)
The recommendations of the consultants require a number of assumptions and modifications to be implemented by Syntex Labs. Presents the initial implementation plan of the company. View Details
Keywords: Organizational Change and Adaptation; Strategic Planning; Salesforce Management; Pharmaceutical Industry
Clarke, Darral G. "Syntex Laboratories (B)." Harvard Business School Case 584-034, September 1983. (Revised November 1984.)
Eugene N. Beesley
The first non-Lilly family member to serve as president, Beesley joined the pharmaceutical company at the age of 20, and worked in a variety of positions before becoming an executive level manger. Under Beesley’s leadership, research and... View Details
Keywords: Healthcare
- 01 Dec 2004
- News
Finding a Balance
Do the rules of business change when a company’s product holds the power of life or death over its customers? That’s a question students must consider when discussing “Cipla,” a case about a $325 million Indian pharmaceutical company that... View Details
- 31 Oct 2004
- Research & Ideas
Bypass Marketing: Are Docs Influenced?
promotional spending (including that directed toward physicians) as a percentage of pharmaceutical sales remains relatively constant over time and thus the growth of DTCA represents a shift in the mix of... View Details
Keywords: by Manda Salls
- 25 Jul 2005
- Research & Ideas
An Organization Your Customers Understand
Imagine an organization made up of a variety of three-dimensional shapes. Rectangular blocks represent the functions: manufacturing, R&D, and sales and marketing. The spheres are regional offices. Pyramids represent product groups—one... View Details
Keywords: by Robert Simons
- 22 Jul 2014
- Blog Post
From FIELD to Field, Putting What I’ve Learned at HBS into Practice
simple and clear as they appeared at first glance. The many times I was pushed to justify my stance – from the morality and ethicality of pharmaceutical patents in the developing world to the negotiation tactics I would use with Steve... View Details
- Student-Profile
Byungyeon Kim
important Harvard’s worldwide research centers would be to his work. His second year research project involved a study of sales force compensation that resulted from a partnership with a Turkish View Details
- 22 Oct 2013
- First Look
First Look: October 22
expenditures on teammates lead to better performance in both sports teams in Canada and pharmaceutical sales teams in Belgium. These results suggest that a minor adjustment to employee bonuses-shifting the... View Details
Keywords: Sean Silverthorne
- 22 Apr 2008
- First Look
First Look: April 22, 2008
Business Harvard Business School Case 608-136 Novartis is a science-based drug company, which has important implications for its business strategy. It is one of the largest pharmaceutical companies in the world with over $38B in View Details
Keywords: Martha Lagace
- 22 Feb 2016
- Research & Ideas
The ‘Mother of Fair Trade’ was an Unabashed Price Protectionist
state pharmaceutical licensing exam, opened a drugstore with her husband in Stockton in 1915. Following his death, she became the sole proprietor and later opened two additional drugstores in town. Gleason emerged as a stalwart defender... View Details
- 01 Jan 2003
- News
Daniel L. Vasella, M.D.
aspirations, purpose, and values, so that they work together as an aligned team." Dan Vasella finds that the skills he called upon as a practicing physician are equally useful in running one of the world's largest pharmaceutical... View Details
- 15 Apr 2014
- News
Bertarelli Foundation Gift Names Deans' Health & Life Sciences Challenge Prize
entrepreneur who has had a successful career in business, finance, yachting, and philanthropy. He is the former CEO of Serono SA (formerly known Ares-Serono), a family-controlled global pharmaceuticals and biotechnology leader whose roots... View Details
- 26 Apr 2004
- Research & Ideas
A Clear Eye for Innovation
is Ciba Vision. Established in the early 1980s as a unit of the Swiss pharmaceutical giant Ciba-Geigy (now Novartis), the Atlanta-based Ciba Vision sells contact lenses and related eye-care products to optometrists and consumers. Although... View Details
- 01 Jan 2002
- News
Raymond V. Gilmartin (MBA '68)
the business world has an important leadership role to play in terms of closing the gap in health and other vital social issues," he says. When Ray Gilmartin joined Merck in June 1994 as president and CEO (he became chairman several months later), it was the first time... View Details
- 01 Sep 2015
- Blog Post
Building a Startup at HBS
prototype which we showcased at HBS and tested out in the NICU to observe its efficacy and nurse uptake. While we each embarked on different paths after the end of first year– from launching a new healthcare venture in Africa, to working at large View Details
- 23 Mar 2010
- First Look
First Look: March 23
catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of side effects, with the... View Details
Keywords: Martha Lagace